Objectives: We conducted a study to evaluate the impact of obesity on erectile function in men with erectile dysfunction. Methods: Three hundred and twenty-five consecutive patients with erectile dysfunction were evaluated. We classified the men into 2 groups according to body weight: <120% of the ideal body weight, and ≥120%. We compared several erectile capacities and the findings of penile duplex ultrasonography. Results: There was a statistically significant decrease in the quality of residual erectile function in patients with obesity (penile rigidity grade 1.32 versus 1.62 in the nonobese patients). Obese patients also have an increased prevalence of vascular risk factors based on a review of the medical records and vascular impairment by duplex ultrasound study (43 and 62% in the obese patients versus 30 and 42% in the nonobese patients, respectively, p < 0.05). However, when we focused only on the patients without any vascular risk factors, no significant difference between the 2 groups was noted in the quality of residual erectile function and also the prevalence of penile vascular impairments (p > 0.05). Conclusions: These data demonstrate that obesity in itself does not seem to be an underlying factor, but does impose a risk to vasculogenic impotence by developing chronic vascular disease.

Keywords:
Obesity, Penile erection, Vascular risk factors, Doppler ultrasound
1.
Foster DW: Eating disorders: obesity and anorexia nervosa; in Wilson JD, Foster DW (eds): William’s Textbook of Endocrinology. Philadelphia, Saunders, 1992, pp 1335–1352.
2.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB: Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol 1994;151:54–61.
3.
Ishii N, Watanabe H, Irisawa C, Kikuchi Y, Kubota Y, Kawamura S, Guzuki K, Chiba R, Tokiwa M, Shirai M: Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol 1989;141:323–325.
4.
Waldhauser M, Schramek P: Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 1988;140:525–527.
5.
Jung R: Endocrinological aspects of obesity. Clin Endocrinol Metab 1984;13:597–612.
6.
Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL: Low serum testosterone and sex hormone binding globulin in massively obese men. J Clin Endocrinol Metab 1977;45:1211–1219.
7.
Schneider G, Kirschner MA, Berkovitz R, Ertel NH: Increased estrogen production in obese men. J Clin Endocrinol Metab 1979;48:633–638.
8.
Prager R, Wallace P, Olefsky JM: Hyperinsulinemia does not copensate for peripheral insulin resistance in obesity. Diabetes 1987;36:327–334.
9.
Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968–977.
10.
Evans DJ, Murray R, Kissebah AH: Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal, and insulin bindings: effects of obesity and body fat topography. J Clin Invest 1984;74:1515–1525.
11.
Vermeulen A: Decreased androgen levels and obesity in men. Ann Med 1996;28:13–15.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.